A World Health Organization (WHO) panel of vaccine experts is set to issue recommendations on Moderna's Covid-19 vaccine on Tuesday.
The WHO had granted emergency use validation for the Pfizer-BioNTech Covid-19 vaccine on December 31, 2020, opening the door for countries to expedite their own regulatory approval processes to import and administer the vaccine.
Now the WHO panel has reviewed data from Moderna's Covid-19 vaccine.
In a media advisory about the next week's event, the WHO said on Friday that the Strategic Advisory Group of Experts (SAGE) on Immunization will make public its interim recommendations to WHO on the use of Moderna Covid-19 (mRNA-1273) vaccine."The recommendations have been agreed at the SAGE extraordinary meeting held on January 21 (Thursday)," said the advisory.
The Moderna Covid-19 vaccine has already been approved for emergency use in several countries, including the US.
The vaccine is administered as two doses, one month apart to prevent Covid-19.
According to a report released by the US Centers for Disease Control and Prevention (CDC) on Friday, over 1,200 adverse events were reported after receipt of Moderna Covid-19 vaccine as of January 10, with 10 cases determined to be anaphylaxis.
Minor adverse events after vaccinations are not uncommon.
While many countries rely on their own regulatory systems for vaccine approvals, some countries with weak system depend on WHO's nod to a great extent for rolling out their national vaccination programmes.
--IANS
gb/ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU